Moreover, decreased expression of CRBP-1 was found relevant to shorter survival time in endometrial carcinoma, ovarian carcinoma and breast carcinoma, while increased expression of CRBP-1 was verified to damage survival time in astrocytic gliomas [26], leiomyosarcoma [27] and lung adenocarcinoma [15]. This evidence concerns the gene RBP1 and ovarian carcinoma.